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Abstract
Fetal brain hypoxic injury remains a concern in high-risk delivery. There is
significant clinical interest in agents that may diminish neuronal damage dur-
ing birth asphyxia, such as in allopurinol, an inhibitor of the prooxidant
enzyme xanthine oxidase. Here, we established in a rodent model the capacity
of allopurinol to be taken up by the mother, cross the placenta, rise to thera-
peutic levels, and suppress xanthine oxidase activity in the fetus. On day 20 of
pregnancy, Wistar dams were given 30 or 100 mg kg1 allopurinol orally.
Maternal and fetal plasma allopurinol and oxypurinol concentrations were
measured, and xanthine oxidase activity in the placenta and maternal and fetal
tissues determined. There were significant strong positive correlations between
maternal and fetal plasma allopurinol (r = 0.97, P < 0.05) and oxypurinol
(r = 0.88, P < 0.05) levels. Under baseline conditions, maternal heart
(2.18  0.62 mU mg1), maternal liver (0.29  0.08 mU mg1), placenta
(1.36  0.42 mU mg1), fetal heart (1.64  0.59 mU mg1), and fetal liver
(0.14  0.08 mU mg1) samples all showed significant xanthine oxidase
activity. This activity was suppressed in all tissues 2 h after allopurinol admin-
istration and remained suppressed 24 h later (P < 0.05), despite allopurinol
and oxypurinol levels returning toward baseline. The data establish a mamma-
lian model of xanthine oxidase inhibition in the mother, placenta, and fetus,
allowing investigation of the role of xanthine oxidase–derived reactive oxygen
species in the maternal, placental, and fetal physiology during healthy and
complicated pregnancy.
Introduction
Despite advances in obstetric practice, acute intrapartum
fetal hypoxia remains one of the most common forms of
fetal stress, with substantial morbidity and mortality (Low
2004). One possible strategy to combat the detrimental
effects of fetal hypoxia would be to decrease the associated
excessive generation of reactive oxygen species (ROS) from
stimulated prooxidant mechanisms within the cell, such as
the xanthine oxidase pathway (Berry and Hare 2004).
Indeed, maternal treatment with the xanthine oxidase
inhibitor allopurinol is being considered in human
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pregnancy complicated by intrapartum hypoxia in order to
protect the infant from excessive generation of ROS (Peet-
ers-Scholte et al. 2003; Benders et al. 2006; Chaudhari and
McGuire 2008; Torrance et al. 2009; Kaandorp et al. 2010,
2011b, 2012). This clinical interest in antenatal maternal
administration of allopurinol follows previous studies
which reported that allopurinol treatment in the asphyxi-
ated neonate improved neonatal outcome (Van Bel et al.
1998), but if the time interval between hypoxia and treat-
ment had been too long, or when fetal hypoxia had been
too severe, no reduction in serious morbidity or mortality
was observed (Benders et al. 2006). Therefore, there has
been growing clinical and scientific interest in establishing
whether perinatal outcome may be improved in compli-
cated labor if the window of treatment with allopurinol
could be initiated before birth, for instance, via maternal
treatment to cover the actual period of fetal hypoxia and
reperfusion (Derks et al. 2010; Kaandorp et al. 2010).
Whereas there have been studies in large animals
including the pregnant ewe (Masaoka et al. 2005; Derks
et al. 2010) and sow (van Dijk et al. 2008), no small ani-
mal model of allopurinol administration to the mother
during pregnancy has been established. Such a model is
indispensable in species with a comparatively shorter life
span to allow follow up of the effects of xanthine oxidase
inhibition during pregnancy on the physiology of the off-
spring in later life. This is essential when many of the
conditions associated with a suboptimal fetal environment
such as cardiovascular disease and type 2 diabetes only
emerge in later life.
Therefore, the aims of this study were to investigate in
rodent pregnancy: (1) whether xanthine oxidase is active
in the placenta, maternal, and fetal tissues in late gesta-
tion; (2) if maternal oral administration of allopurinol
could increase maternal plasma levels of allopurinol and
its active metabolite oxypurinol; (3) if maternal allopuri-
nol and oxypurinol could cross the placenta, yielding
therapeutic levels in the fetal circulation; and (4) whether
elevations in maternal and fetal plasma levels of allopuri-
nol and oxypurinol resulted in suppression of xanthine
oxidase activity in the placenta, maternal, and fetal
tissues. These aims were determined using a clinically
relevant dose of allopurinol (30 mg kg1), comparable
to the dose given in previous human studies (Van
Bel et al. 1998; Benders et al. 2006), and a larger dose
(100 mg kg1) to investigate any pharmacological benefit
in terms of either greater fetal levels of allopurinol and/or
longer inhibition of xanthine oxidase activity.
Materials and Methods
All procedures involving animals were carried out under
the Animals (Scientific Procedures) Act 1986 and
approved by the Local Ethics Review Committee of the
University of Cambridge, U.K. Thirty-five time-mated
pregnant Wistar rats (Charles River Limited, Margate,
U.K.) were delivered to the University of Cambridge
between 10 and 14 days of gestation and were individu-
ally housed under standard conditions (21  1°C, 55%
humidity, and 12 h/12 h light/dark cycle) with free access
to food and water.
On day 20 of pregnancy all animals were randomized
to either control or allopurinol treatment. Allopurinol
(30 mg kg1 or 100 mg kg1, Sigma, U.K., suspended in
3 mL Hartley’s Strawberry Jelly) was placed in a clear
glass bowl inside the cage at 8 AM. Animals had been
given an untreated jelly dose the day before to condition
them to eat it. Following allopurinol treatment, animals
underwent euthanasia (CO2 followed by cervical disloca-
tion) at 2, 6, or 24 h following administration (n = 5 all
time points and doses). A further five animals underwent
euthanasia at 8 AM on day 20 of pregnancy to act as con-
trols. Following euthanasia, a maternal blood sample was
taken by cardiac puncture for the measurement of mater-
nal circulating allopurinol and oxypurinol levels. Fetal rats
were then exposed by laparotomy. The fetuses were sub-
jected to cervical transection, and blood was collected and
pooled from all fetuses. Maternal and fetal blood samples
were anticoagulated with ethylenediaminetetraacetic acid
(EDTA), centrifuged (3000 g for 5 min), and the plasma
was frozen in liquid nitrogen and subsequently stored at
80°C until analysis for allopurinol and oxypurinol. Sam-
ples of placenta, maternal heart, maternal liver, and fetal
liver of ca. 100 mg were taken, weighed, and homoge-
nized in buffer (1 mL of 100 mmol L1 TRIS-HCl, pH
7.5 with 10 lL protease inhibitor cocktail, SIGMA,
P8340). Fetal heart samples were ca. 20–25 mg. All further
analysis was adjusted for the weight of tissue taken. Fetal
tissue samples and associated placentas were taken only
from male pups to reduce any differences attributable to
sex. The sex of each fetal pup was determined by their
anogenital distance as previously described (Camm et al.
2010). Following centrifugation of the tissue homogenate
(30 min, 10,000 g at 4°C), the supernatant was decanted
and frozen in aliquots at 80°C until further analysis.
Plasma allopurinol and oxypurinol
measurements
Allopurinol and oxypurinol plasma concentrations were
determined by using reversed-phase, high-performance
liquid chromatography with ultraviolet detection at
254 nm for the quantification of allopurinol and oxypuri-
nol in plasma (van Kesteren et al. 2006). The method was
linear between 0.5 and 25 lg mL1 with a lower limit of
detection of 0.2 lg mL1 for both compounds.
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Xanthine oxidase assay
Fetal plasma xanthine oxidase activity levels were mea-
sured using a commercially available assay kit (A22182;
Invitrogen, Paisley, U.K.). The assay works on the princi-
ple that xanthine oxidase produces superoxide anions. In
vitro, superoxide spontaneously degrades to hydrogen
peroxide (H2O2). H2O2, in the presence of horseradish
peroxidase (HRP), reacts stoichiometrically with Amplex
Red reagent to generate the red-fluorescent oxidation
product, resorufin. In brief, 50 lL of tissue homogenate
or xanthine oxidase standard solution was added to
50 lL of 100 lmol/L Amplex Red reagent solution which
also contained 0.4 U mL1 HRP and 200 lmol/L hypo-
xanthine. The resulting solutions were mixed and then
incubated for 30 min at 37°C. The presence of resorufin
was detected by fluorescence using excitation in the range
530–560 nm and emission detection at 590 nm. Activity
was then expressed per mg of wet tissue.
Data and statistical analysis
All values are expressed as mean  SEM. The correlation
between fetal and maternal allopurinol and oxypurinol
levels was assessed using the Pearson product moment
correlation (Sigma-Stat 3.5; Chicago, IL). Allopurinol,
oxypurinol and xanthine oxidase activity levels were com-
pared using one-way analysis of variance (ANOVA) com-
paring with reference to time 0 h. Where significant
differences were found, the Student–Newman–Keuls post
hoc test was applied (Sigma-Stat 3.5; Chicago, IL). Statis-
tical significance was accepted when P < 0.05.
Results
Allopurinol and oxypurinol levels in
maternal and fetal plasma
Administration of 30 mg kg1 and 100 mg kg1 allopuri-
nol to the pregnant rat led to increases in both maternal
and fetal allopurinol and oxypurinol by 2 h (Fig. 1). Fol-
lowing the administration of allopurinol at both doses of
30 mg kg1 and 100 mg kg1, allopurinol levels returned
to baseline at 6 h following dosing; however, oxypurinol
levels remained significantly elevated in both mother and
fetus. Although maternal and fetal plasma oxypurinol lev-
els were detectable 24 h following dosing, they were not
significantly different from baseline.
When all paired maternal and fetal plasma concentra-
tions of allopurinol and oxypurinol were related to deter-
mine maternal-to-fetal transfer, a significant positive
correlation was obtained for both compounds (P < 0.05;
Fig. 2). The correlation coefficient (r) for the relationship
between maternal and fetal allopurinol was 0.97, and
between maternal and fetal oxypurinol was 0.88, indicat-
ing a high degree of correlation (Fig. 2).
Plasma xanthine oxidase levels
Xanthine oxidase activity was detectable in maternal heart,
maternal liver, placenta, fetal heart, and fetal liver (Fig. 3).
Maternal and fetal cardiac tissue displayed the greatest
activity (2.17  0.6 mU mg1 and 1.65  0.59 mU
mg1, respectively), followed by placenta (1.36  0.41 mU
mg1), and then maternal liver and fetal liver (0.29 
0.09 mU mg1 and 0.14  0.08 mU mg1). Treatment
with allopurinol at 30 mg kg1 and 100 mg kg1 signifi-
cantly depressed activity in all tissues by 2 h and this sup-
pression was sustained 6 and 24 h following treatment.
Discussion
Despite intense basic science research and clinical trials
investigating the potential neuroprotective effects of the
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Figure 1. Maternal and fetal plasma allopurinol and oxypurinol
measurements. Values are mean  SEM for allopurinol (○) and
oxypurinol (●) concentrations in maternal and fetal plasma (n = 5
per time point and group) at 0, 2, 6, and 24 h postadministration
of (A) 30 mg kg1, and (B) 100 mg kg1 of allopurinol to the
mother at time 0 h. One-way ANOVA with post hoc Student–
Newman–Keuls where appropriate. Significant differences
(P < 0.05): *, versus 0 h control.
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xanthine oxidase inhibitor allopurinol on the fetal brain
during and following acute fetal hypoxia (Boda et al.
1984; Van Bel et al. 1998; Benders et al. 2006; Derks et al.
2006, 2010; van Dijk et al. 2008; Kaandorp et al. 2010,
2011a,b), no animal model exists that offers the possibil-
ity of maternal administration of allopurinol and long-
term follow up of the treated offspring. Here, we show
that allopurinol administered orally to the pregnant rat
during late pregnancy leads to therapeutic rises in circu-
lating allopurinol and oxypurinol in the mother and fetus.
The increased levels achieved were functionally relevant as
demonstrated by significantly reduced, xanthine oxidase
activity levels in the placenta, and maternal and fetal tis-
sues following 24 h of maternal allopurinol administra-
tion. The level of suppression of xanthine oxidase activity
was similar with the low and high doses of maternal allo-
purinol administration.
Currently, human clinical studies based in the Nether-
lands are assessing whether antenatal allopurinol adminis-
tration during intrapartum fetal hypoxia can reduce
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Figure 2. Maternal to fetal allopurinol and oxypurinol correlations. Values are paired maternal and fetal (A) allopurinol and (B) oxypurinol
concentrations at all time points and both 30 mg kg1 and 100 mg kg1 allopurinol dosing protocols. N = 35 paired samples per analysis.
Both relationships show significant positive correlation (P < 0.05, Pearson correlation).
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Figure 3. Maternal, fetal, and placental xanthine oxidase activity. Values are mean  SEM for tissue xanthine oxidase activity in samples of
maternal heart and liver, planceta, fetal heart, and liver maternal and fetal organ activities of xanthine oxidase assayed in vitro at 0, 2, 6, and
24 h following oral administration of allopurinol to the pregnant dam on day 20 of pregnancy (■, 0 h control; , 30 mg kg1; , 100 mg kg1;
n = 5 per time point). One-way ANOVA with post hoc Student–Newman–Keuls where appropriate. Significant differences (P < 0.05): *, versus
0 h control.
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overall morbidity and mortality in the newborn (Kaan-
dorp et al. 2010, 2012, 2013). Recent follow-up data from
those trials suggest that there may be a reduction in the
relative risk of severe disability between 4 and 8 years of
age in children who were moderately asphyxiated intra-
partum but received postnatal allopurinol treatment start-
ing within 4 h after birth (Kaandorp et al. 2012).
Importantly, postnatal allopurinol was not associated with
any negative side effects in the children who were fol-
lowed up (Kaandorp et al. 2012). The rationale behind
moving clinical therapy from postnatal to antenatal allo-
purinol administration is that by shortening the period
between the beginning of ROS production and the anti-
oxidant cover, the overall tissue injury, and thereby clini-
cal disability, may be reduced. In support of this
hypothesis, we have recently reported that maternal ante-
natal allopurinol administration can reduce hippocampal
brain damage in an ovine model of repeated birth
asphyxia (Kaandorp et al. 2013).
Previous reports have confirmed that maternal treat-
ment with allopurinol crosses the ovine (Masaoka et al.
2005; Derks et al. 2010), porcine (van Dijk et al. 2008),
and human (Boda et al. 1999; Torrance et al. 2009) pla-
centa to increase fetal plasma concentrations of allopuri-
nol and oxypurinol. In sheep, a dose of 20 mg kg1 i.v.
to the maternal ewe led to peak maternal allopurinol and
oxypurinol concentrations of 47 and 17 lg mL1, respec-
tively, and allopurinol concentrations of approximately
5 lg mL1 in the fetus (Derks et al. 2010). In a pregnant
sow and piglet model, 15 mg kg1 allopurinol given
intravenously to the mother led to fetal peak concentra-
tions of 5 lg mg1 (van Dijk et al. 2008). In this study,
the plasma levels of allopurinol and oxypurinol reached
3.3 lg mg1 and 8.5 lg mg1, respectively, in maternal
plasma and 2.1 lg mg1 and 4.0 lg mg1, respectively,
in fetal plasma for the 30 mg kg1 oral dose, values that
are slightly lower than those measured in the sheep and
pig for doses of similar magnitude. This may reflect spe-
cies differences in the pharmacokinetics of allopurinol
(Goodman et al. 2005). For example, there may be
reduced bioavailability of allopurinol and oxypurinol fol-
lowing oral administration relative to other routes of
administration and/or differences in drug transfer across
the placenta. It is also possible that basal xanthine oxidase
activity in the rodent dam and its fetus may be different,
altering the rate of conversion of allopurinol into oxypur-
inol. Finally, differences in the clearance of allopurinol
and oxypurinol from the circulation may also exist. Fol-
lowing treatment with 100 mg kg1 of allopurinol to the
mother, fetal values of allopurinol and oxypurinol were
11.6 lg mg1 and 5.2 lg mg1 at 2 h, respectively. It
might have been expected that these values would be
approximately three times greater than those recorded fol-
lowing 30 mg kg1. However, given that xanthine oxidase
catalyzes the conversion of allopurinol to oxypurinol, and
that this reaction is prevented by oxypurinol as the active
metabolite, the production of oxypurinol may prevent
conversion of allopurinol into oxypurinol, leading to a
relatively high allopurinol concentration and therefore
decreasing the rate of further generation of oxypurinol
(Parks and Granger 1986; Berry and Hare 2004). There
was also a high correlation between paired maternal and
fetal concentrations of allopurinol and oxypurinol, inde-
pendent of time point of dose, indicating that placental
transfer is reliable and consistent. However, fetal levels of
allopurinol and oxypurinol were lower than maternal,
reflected by the coefficient of the straight line relationship
being <1.
Effective inhibition of xanthine oxidase has been
previously reported in the adult rat over the range of
allopurinol doses from 2 to 50 mg kg1 (Klein et al.
1996). In the sheep fetus, concentrations of allopurinol
of 2.25 lg mL1 achieved a lowering of ROS production
(Masaoka et al. 2005), and 5 lg mL1 allopurinol incre-
ased umbilical blood flow following umbilical cord occlu-
sion (Derks et al. 2010). In ovine pregnancy, larger doses
of allopurinol led to suppression of a1-mediated vasocon-
striction in the fetal femoral vascular bed via decreasing
ROS-mediated NO depletion in the circulation (Herrera
et al. 2012). In this study, allopurinol concentrations as
low as 2.1 lg mL1 were sufficient to inhibit xanthine
oxidase activity in the fetal rat, with higher doses not
offering greater inhibition. Despite the decrease in allopu-
rinol and oxypurinol levels over the 24 h period
examined in this experiment, xanthine oxidase activity
was still suppressed in all tissues investigated. Therefore,
doses of allopurinol as low as 30 mg kg1 administered
to the mother are effective to promote the long-term
suppression of xanthine oxidase activity in placenta and
the fetal organs.
In summary, this study in rodent pregnancy has estab-
lished a human clinically relevant model of maternal allo-
purinol administration that leads to therapeutic
concentrations of allopurinol and oxypurinol in the fetal
circulation. A single dose of 30 mg kg1 allopurinol is
sufficient to suppress xanthine oxidase activity in the
mother, placenta, and fetus for at least 24 h. The model
is indispensable to investigate the long-term consequences
of maternal treatment with allopurinol on the physiology
of the offspring, and to establish the lasting safety of xan-
thine oxidase inhibition in human high-risk pregnancy in
current clinical obstetric practice.
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